TL;DR
The FDA classified a Vitruvias Therapeutics recall of 30-mg thyroid tablets as Class I, its most serious category. New research linked GLP-1 drugs in adolescents to nutritional deficiencies, and the ADA and EASD issued updated consensus guidelines for adult type 1 diabetes care.
The FDA has designated Vitruvias Therapeutics’ recall of a lot of 30-mg levothyroxine-liothyronine tablets as Class I, its most serious classification, meaning exposure to the product could cause serious harm or death, according to a report summarized by MedPage Today on September 29, 2026, citing USA Today. The same roundup collected several other developments in endocrinology, including research linking GLP-1 drugs in adolescents to nutritional deficiencies and updated joint consensus guidelines for managing type 1 diabetes in adults from the American Diabetes Association and the European Association for the Study of Diabetes.
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The recalled product is a lot of Thyroid Tablets combining levothyroxine and liothyronine at the 30-mg strength. A Class I designation is the FDA’s most serious recall category, reserved for situations where use of, or exposure to, a violative product carries a reasonable probability of serious adverse health consequences or death. Patients taking the affected medication are typically advised to contact their pharmacist or prescribing physician before stopping treatment, since abruptly discontinuing thyroid hormone replacement can be harmful. The specific defect prompting the recall was not detailed in the roundup.
On the GLP-1 research front, a study published in Childhood Obesity found that nearly 17% of adolescents taking a GLP-1 drug were diagnosed with at least one nutritional deficiency — most frequently vitamin D deficiency — within the first year of starting the medication. A separate preprint posted at Preprints.org suggested that a patient’s weight trajectory in the years before starting a GLP-1 drug may help predict whether they become a “super responder.” Because the latter finding comes from a preprint that has not yet undergone peer review, it should be treated as preliminary.
In guideline news, the American Diabetes Association and EASD issued updated joint consensus guidelines for managing type 1 diabetes in adults, published in Diabetes Care. The roundup did not enumerate the specific changes in the new guidance, and readers are directed to the published document for the full recommendations.
What the Recall Class Means for Patients
The Class I designation matters because thyroid hormone replacement is typically taken daily and indefinitely; a quality defect in a widely used tablet strength can affect a large population of patients who depend on consistent, precise dosing. Both too much and too little thyroid hormone can cause clinically serious problems, including cardiac effects, which is why the FDA reserves its strictest recall classification for such products.
The adolescent nutrition findings matter as GLP-1 prescribing in young people expands. The study suggests clinicians may need to monitor vitamin D and other nutrient levels more routinely in the first year of GLP-1 therapy. The updated T1D guidelines are similarly consequential for the adult type 1 diabetes population, as joint ADA-EASD consensus documents shape clinical practice internationally.
Products Worth Considering

Garmin Forerunner 570 GPS Running Smartwatch, 42 mm, Aluminum Bezel, Bone/Mango

Withings Body Scan Smart Scale

Philips Sonicare 7300 Rechargeable Electric Toothbrush with 3 Brush Heads, Black
As an affiliate, we earn on qualifying purchases.
A Busy Stretch in Obesity Drug News
The thyroid recall landed during a period of heavy news in metabolic medicine. Eli Lilly reported at the EASD annual meeting that tirzepatide (Zepbound) yielded greater weight loss than semaglutide (Wegovy HD) in an indirect comparison of trials, and that its oral GLP-1 drug orforglipron (Foundayo) was associated with greater weight loss and HbA1c reduction versus oral semaglutide (Rybelsus) in an indirect comparison of type 2 diabetes trials. Indirect comparisons cannot substitute for head-to-head trials.
Novo Nordisk countered with data indicating that adults with type 2 diabetes on semaglutide (Ozempic) who doubled their dose had a lower risk of major adverse cardiovascular events than those switching to tirzepatide (Mounjaro). Roche halted development of emugrobart, an investigational muscle-building drug intended to pair with GLP-1/GIP receptor agonists, after a disappointing interim phase II analysis. Viking Theratives reported that participants maintained virtually all weight loss after switching from weekly to less frequent dosing of its investigational obesity drug in phase II. Separately, Merck announced that the tri-specific agonist remigromig demonstrated noninferiority to ranibizumab (Lucentis) on vision outcomes for diabetic macular edema in a phase IIb/III trial.
“The FDA designated Vitruvias Therapeutics’ recall of a lot of 30-mg levothyroxine-liothyronine tablets as Class I, its most serious classification.”
— MedPage Today roundup (citing USA Today)
Unanswered Questions in the Findings
Several items in the roundup remain preliminary or incomplete. The specific defect behind the thyroid tablet recall, and whether any patient injuries have been reported, were not stated. The “super responder” weight-trajectory finding is a non-peer-reviewed preprint. The Lilly and Novo Nordisk comparisons are indirect comparisons of separate trials, not head-to-head studies, which limits the strength of the conclusions. The specific contents of the new ADA-EASD type 1 diabetes guidelines were not summarized in the source material.
Watchpoints for Recall and Guidelines
Patients who take 30-mg levothyroxine-liothyronine tablets can check with their pharmacy to determine whether their prescription comes from the affected lot, and regulators may release further recall details as the investigation proceeds. The adolescent nutrition study and the super-responder preprint are likely to draw follow-up research, and the peer review status of the preprint may change. Clinicians can expect the updated ADA-EASD consensus guidelines to begin informing adult type 1 diabetes care standards, with full details available in Diabetes Care.
Key Questions
What does a Class I recall mean?
Class I is the FDA’s most serious recall classification. It applies when exposure to a violative product carries a reasonable probability of serious adverse health consequences or death.
Which thyroid drug was recalled?
A lot of Vitruvias Therapeutics’ 30-mg levothyroxine-liothyronine tablets, marketed as Thyroid Tablets. Patients should verify lot numbers with their pharmacist rather than stopping medication on their own.
Are GLP-1 drugs linked to vitamin deficiencies in teens?
One study in Childhood Obesity found nearly 17% of adolescents on a GLP-1 drug developed at least one nutritional deficiency, most often vitamin D, within the first year. The study shows an association, not a proven causal mechanism.
Did Zepbound beat Wegovy in a head-to-head trial?
No. Eli Lilly’s finding came from an indirect comparison of separate trials presented at the EASD meeting. Indirect comparisons are weaker evidence than head-to-head studies.
What did the new type 1 diabetes guidelines cover?
The American Diabetes Association and EASD issued updated joint consensus guidelines for managing type 1 diabetes in adults, published in Diabetes Care. The specific recommendations were not detailed in the initial roundup.
Source: rss
